Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 1;31(6):356-366.
doi: 10.4103/sjg.sjg_32_25. Epub 2025 Oct 3.

Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients

Hamdan S AlGhamdi  1   2   3 , Nawaf M AlYahya  4 , Ibrahim M Bahabri  5 , Majed A Al Ashaikh  5 , Abdulrahman K Habib  5 , Abdulaziz A AlAhmary  5 , Nuha Al Ajlan  5 , Abdulrahman I AlAbdulgader  4 , Abduljaleel M Alalwan  1   2   3 , Faisal M Sanai  6
Affiliations

Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients

Hamdan S AlGhamdi et al. Saudi J Gastroenterol. .

Abstract

Background:: Primary sclerosing cholangitis (PSC) is often associated with inflammatory bowel disease (IBD). We aimed to compare the clinical presentations and outcomes of PSC in patients with and without IBD in Saudi population.

Methods:: The medical records of patients with PSC, diagnosed between 2009 and 2020, in a single referral center in Saudi Arabia were reviewed. Primary outcomes included liver-related clinical decompensations, while secondary outcomes encompassed hepatobiliary malignancies, liver-related mortality, and liver transplantation.

Results:: Among 87 patients, 52 (59.8%) had PSC-IBD and 35 (40.2%) had PSC without IBD. PSC-IBD patients were significantly younger at diagnosis (35.4 ± 13.3 vs. 43.6 ± 12.8 years, P = 0.005). Non-IBD patients exhibited higher rates of diabetes (P = 0.045), hyperlipidemia (P = 0.022), and autoimmune hepatitis (P = 0.008). While clinical presentations were similar, non-IBD patients demonstrated more frequent cytopenia from splenomegaly (31.4% vs. 5.8%, P = 0.001) and hepatic decompensation (37.1% vs. 7.7%, P = 0.001). Bilirubin (P = 0.002) and aspartate aminotransferase (P = 0.042) levels were increased in non-IBD patients, while PSC-IBD patients had higher white blood cell (P = 0.021) and platelet counts (P < 0.001). Liver biopsies were more frequently performed in non-IBD patients (45.7% vs. 19.2%, P = 0.008). Overall mortality was 12.8%, with no difference in median survival time between groups (P = 0.782). Multivariate analysis identified age (hazard ratio [HR]: 1.048, P = 0.044) and MELD-Na (HR: 1.155, P = 0.016) as independent predictors of mortality.

Conclusion:: In this Saudi cohort, non-IBD PSC patients were diagnosed later and presented with more comorbidities and hepatic decompensation. However, IBD status did not impact overall survival. Older age and higher MELD-Na scores at presentation were significant risk factors for mortality in PSC patients.

Keywords: Biliary diseases; cirrhosis; inflammatory bowel disease; overall survival.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Mortality of PSC patients stratified by IBD and liver transplantation
Figure 2
Figure 2
Survival analysis between PSC patients with and without IBD
See this image and copyright information in PMC

References

    1. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis-a comprehensive review. J Hepatol. 2017;67:1298–323. - PubMed
    1. Dyson JK, Beuers U, Jones DE, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391:2547–59. - PubMed
    1. Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications:An algorithmic approach. Hepatology International. 2021;15:6–20. - PMC - PubMed
    1. Sohal A, Kayani S, Kowdley KV. Primary sclerosing cholangitis:Epidemiology, diagnosis, and presentation. Clin Liver Dis. 2024;28:129–41. - PubMed
    1. Trivedi PJ, Bowlus CL, Yimam KK, Razavi H, Estes C. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis:A systematic review of population-based studies. Clin Gastroenterol Hepatol. 2022;20:1687–700.e4. - PubMed

LinkOut - more resources